A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Inclusion Criteria: 1. Aged ≥ 18 years old on the day of signing the informed consent form; 2. Diagnosed as stage III-IV or recurrent ovarian cancer; 3. Have surgical indications and no contraindications to surgery, and voluntarily undergo laparotomy or laparoscopic surgery to treat ovarian cancer; 4. Understand the research procedures and methods, voluntarily participate in this trial, and sign the written informed consent form. Exclusion Criteria: 1. The primary site of the tumor is not the ovary or there is brain metastasis; 2. A history that may increase the risk of bleeding; 3. A history of VTE in the past or during screening, or a disease that increases thrombosis tendency such as protein C deficiency; 4. Patients with atrial fibrillation requiring anticoagulant treatment or the use of artificial heart valves during screening; 5. Acute coronary syndrome within 3 months; 6. Poorly controlled hypertension before screening, and uncontrolled hypertension within 6 months severe cardiac arrhythmia; 7. Any laboratory test indicator during screening or baseline does not meet the standards in the exclusion criteria; 8. Have had a history of adverse reactions or allergies related to rivaroxaban or enoxaparin, such as heparin-induced thrombocytopenia; 9. Have used any drugs prohibited other than investigational drugs within 7 days before screening or plan to use during the study; 10. Those who have participated in any drug intervention clinical trial within 1 month before screening, or those who are within 5 half-lives of the investigational drug at the time of screening, Whichever is longer; 11. Those who are expected to use postoperative neuraxial analgesia; 12. Those who are expected to use plantar vein pumps, intermittent pneumatic compression devices, electronic or mechanical muscle stimulators after surgery; 13. Other circumstances in which the researcher believes that the subject is not suitable to participate in this trial.